NRSN vs ACIU vs PRTA vs SAVA

For growth investors, AC Immune S.

A. (ACIU) is the stronger pick with -86. 9% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate AC Immune S. A. (ACIU) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AC Immune S.

A. (ACIU) delivered a total return of -52. 4%, compared to -78. 3% for NeuroSense Therapeutics Ltd. (NRSN). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus ACIU's -81. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Prothena Corporation plc (PRTA) is the lower-risk stock at 0.

96β versus Cassava Sciences, Inc. 's 1. 99β — meaning SAVA is approximately 108% more volatile than PRTA relative to the S&P 500. On balance sheet safety, NeuroSense Therapeutics Ltd. (NRSN) carries a lower debt/equity ratio of 3% versus 10% for AC Immune S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AC Immune S.

A. (ACIU) is pulling ahead at -86. 9% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, ACIU leads at -3. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NeuroSense Therapeutics Ltd.

(NRSN) is the more profitable company, earning 0. 0% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRSN leads at 0. 0% versus -1927. 3% for ACIU. At the gross margin level — before operating expenses — ACIU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ACIU: 138.

9% to $7. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Prothena Corporation plc (PRTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

96)). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRTA: -72. 5%, SAVA: -19. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.